Novartis AG, Merck & Co. Inc. and Allergan Plc were among companies that raised U.S. prices on more than 100 prescription medicines, bringing the tally to 445 drugs that will cost more in 2020, according to data analyzed by healthcare research firm 3 Axis Advisors.

Bristol-Myers Squibb Co. and Celgene Corp. won U.S. antitrust approval for their merger on condition that they sell Celgene’s psoriasis drug Otezla.

Eli Lilly third-quarter 2019 sales missed Wall Street estimates as rebates limited revenue from the drug manufacturer’s top-selling diabetes medicine Trulicity, and shares fell about 4 percent.

A little more than a week after announcing plans to acquire Ra Pharmaceutical for $2.1 billion, UCB’s psoriasis drug bimekizumab met all endpoints in the first of three Phase III studies.

Southern California-based Sienna Biopharmaceuticals filed for bankruptcy, which sent share prices tumbling more than 73 percent.

Amgen will buy Celgene’s psoriasis drug Otezla for $13.4 billion in cash, clearing the way for Bristol-Myers Squibb to go ahead with the company’s $74 billion deal for Celgene by the end of 2019.

Humira’s dominance continues as the world’s top-selling prescription product as the biologic therapy is the first drug to exceed $20 billion in annual global sales.

LEO Pharma Inc announced the U.S. Food and Drug Administration expanded the approved indication for Enstilar (calcipotriene and betamethasone dipropionate) Foam, 0.005%/0.064%, for the topical treatment of plaque psoriasis to include patients age 12 and older. Additionally, the FDA approved Taclonex (calcipotriene and betamethasone dipropionate) Topical Suspension in the topical treatment of scalp and body plaque psoriasis in patients 12 years and older.

Bristol-Myers Squibb Co. offered to divest Celgene Corp.’s psoriasis treatment Otezla to allay concerns raised by the U.S. competition regulator, and pushed back the closing of their $74 billion deal.

The U.S. FDA approved AbbVie Inc.’s Skyrizi as a treatment for plaque psoriasis at a time when the company’s blockbuster psoriasis medicine Humira faces patent pressures.